Two Sigma Investments LP cut its stake in shares of Organogenesis Holdings Inc (NASDAQ:ORGO) by 45.1% in the first quarter, Holdings Channel reports. The fund owned 46,761 shares of the company’s stock after selling 38,487 shares during the period. Two Sigma Investments LP’s holdings in Organogenesis were worth $151,000 at the end of the most recent reporting period.
Several other large investors have also recently modified their holdings of the company. State Street Corp boosted its holdings in shares of Organogenesis by 30.9% in the 4th quarter. State Street Corp now owns 164,760 shares of the company’s stock worth $792,000 after acquiring an additional 38,917 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Organogenesis by 97.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 116,488 shares of the company’s stock valued at $561,000 after purchasing an additional 57,572 shares during the last quarter. Tower Research Capital LLC TRC acquired a new position in Organogenesis in the fourth quarter worth $58,000. Bank of Montreal Can grew its holdings in shares of Organogenesis by 12,569.7% during the fourth quarter. Bank of Montreal Can now owns 117,068 shares of the company’s stock worth $563,000 after purchasing an additional 116,144 shares during the last quarter. Finally, Barclays PLC grew its holdings in shares of Organogenesis by 214.3% during the fourth quarter. Barclays PLC now owns 16,324 shares of the company’s stock worth $79,000 after purchasing an additional 11,130 shares during the last quarter. Institutional investors own 3.63% of the company’s stock.
Several research firms recently weighed in on ORGO. BidaskClub cut shares of Organogenesis from a “hold” rating to a “sell” rating in a research report on Friday, May 15th. Zacks Investment Research lowered Organogenesis from a “hold” rating to a “sell” rating in a research note on Wednesday, June 10th. Credit Suisse Group reiterated a “buy” rating on shares of Organogenesis in a research report on Tuesday, March 10th. Oppenheimer started coverage on shares of Organogenesis in a research report on Tuesday, May 12th. They set a “buy” rating and a $8.00 target price on the stock. Finally, BTIG Research reaffirmed a “buy” rating and issued a $8.00 target price on shares of Organogenesis in a research note on Thursday, June 11th. Two equities research analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. Organogenesis presently has an average rating of “Hold” and an average target price of $6.85.
Organogenesis (NASDAQ:ORGO) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.16) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.03). Organogenesis had a negative net margin of 15.48% and a negative return on equity of 124.66%. The firm had revenue of $61.73 million during the quarter, compared to the consensus estimate of $61.30 million. Sell-side analysts predict that Organogenesis Holdings Inc will post -0.69 earnings per share for the current year.
Organogenesis Company Profile
Organogenesis Holdings Inc, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types.
Further Reading: What is a Reverse Stock Split?
Want to see what other hedge funds are holding ORGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organogenesis Holdings Inc (NASDAQ:ORGO).
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.